Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell transcriptomics uncovers endothelial progenitor-like remodelling driving human coronary atherosclerosis progression.

Nature cell biology·2026
Same author

Energy-efficient electrochemical ammonia removal enabled by replacing hydrogen evolution with four-electron oxygen reduction at the cathode.

Water research·2026
Same author

The APT1-NACsa3-GGP1 Module Enhances Salt Tolerance and Regulates Ascorbic Acid Biosynthesis in Medicago.

Plant, cell & environment·2026
Same author

Potassium thiocyanate-promoted four-component alkoxysulfenylation of styrenes with imidazo[1,2-<i>a</i>]pyridines and alcohols.

RSC advances·2026
Same author

Ligand-Regulated Metallaphotoredox Aminoarylation for the Valorization of Feedstock Alkenes.

Journal of the American Chemical Society·2026
Same author

EPHX2 Orchestrates Intestinal Epithelial Barrier Repair in Ulcerative Colitis: An Integrated Multi-Omics and Experimental Study.

Clinical and translational science·2026

Related Experiment Video

Updated: Jul 22, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

MDM2-Targeting Reassembly Peptide (TRAP) Nanoparticles for p53-Based Cancer Therapy.

Fangzhou Li1, Delin Chen2, Qianqian Sun3

  • 1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, No. 11, First North Road, Zhongguancun, Beijing, 100190, P. R. China.

Advanced Materials (Deerfield Beach, Fla.)
|July 20, 2023
PubMed
Summary

Researchers developed novel nanoparticles (MtrapNPs) that trap MDM2, restoring p53 function. This strategy shows promise for treating both p53-wild-type and p53-mutated tumors, offering a new avenue in oncotherapy.

Keywords:
ARFMDM2 traparsenic trioxidecancer therapymutant p53peptideswild-type p53

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.3K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.3K

Related Experiment Videos

Last Updated: Jul 22, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.3K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.3K

Area of Science:

  • Oncology
  • Nanotechnology
  • Molecular Biology

Background:

  • Gene mutations and functional inhibition of p53 impede effective oncotherapy.
  • Mechanisms of p53 inhibition in p53-wild-type tumors remain largely unknown.
  • Decreased expression of ARF, an MDM2 inhibitor, is observed in p53-wild-type tumors.

Purpose of the Study:

  • To investigate ARF's role in p53-wild-type tumor development.
  • To develop a novel nanoparticle strategy targeting MDM2 for p53-based cancer therapy.
  • To evaluate the therapeutic efficacy of MDM2-targeting nanoparticles in p53-mutated and p53-wild-type tumors.

Main Methods:

  • Development of ARF-mimetic MDM2-targeting reassembly peptide nanoparticles (MtrapNPs).
  • Investigation of MtrapNPs' interaction with MDM2 and subsequent p53 activation.
  • In vivo evaluation of MtrapNPs loaded with arsenic trioxide in orthotopic and metastatic p53-mutated tumor models.

Main Results:

  • MtrapNPs effectively trap MDM2, stabilizing and activating p53 in p53-wild-type tumors.
  • Restoring ARF expression is identified as a potential oncotherapy strategy.
  • MtrapNPs loaded with arsenic trioxide demonstrated significant therapeutic effects in p53-mutated tumor models.
  • A link between decreased ARF expression and p53-wild-type tumor development is established.

Conclusions:

  • The MDM2-trap strategy effectively addresses both p53 inhibition and mutations.
  • MtrapNPs represent a promising platform for p53-based tumor therapy.
  • Targeting MDM2 offers a viable approach for treating a broad spectrum of p53-related cancers.